Search Results 101-110 of 16536 for Cirrhosis

  1. Cohort of Patients With Fatty Liver Disease - Mayo Clinic

    ... cirrhosis, liver cancer, and end-stage liver disease. Participation ... Biliary cirrhosis;; Consume ≥ 20 grams of alcohol/day or > 1 drink/day for ...

  2. 6 signs your patient is ready for liver transplant referral - Mayo Clinic

    HCC. Patients diagnosed with cirrhosis require biannual screening for hepatocellular carcinoma (HCC), which is a common liver transplant indication, says ...

  3. Post-transplant NASH Protocol to Assess the Development of Metabolic Co-morbidities and Disease Recurrence in Patients Transplanted for NASH Cirrhosis - Mayo Clinic

    Post-transplant NASH Protocol to Assess the Development of Metabolic Co-morbidities and Disease Recurrence in Patients Transplanted for NASH Cirrhosis.

  4. Engineering stem cells to treat liver disease - Mayo Clinic News Network

    While the liver has a remarkable ability to regenerate, chronic conditions such as cirrhosis, hepatitis and fatty liver disease can quickly progress to end- ...

  5. Mayo Clinic researchers identify potential new therapy for liver diseases

    ROCHESTER, Minn. — Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, ...

  6. Transplant Medicine Calculators - Medical Professionals - Mayo Clinic

    Post-operative Mortality Risk in Patients with Cirrhosis ...

  7. Nonalcoholic Steatohepatitis (NASH) Clinical Trials - Mayo Clinic Research

    Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis Rochester, MN. This is a multicenter, double-blind, randomized, ...

  8. Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension - Mayo Clinic

    This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ...

  9. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Cirrhosis - Mayo Clinic

    Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Cirrhosis. Print ...

  10. A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Cirrhosis- FALCON 1 Study - Mayo Clinic

    A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Cirrhosis- FALCON 1 Study · Share · Facebook ...